Amplifon completes €453M private placement to fund GN Hearing acquisition
What's the deal? Italian hearing solutions company AmplifonDealroom has a profile for this one. Try Dealroom → has completed a €453M private placement, issuing 45.3 million new shares at €10 each to qualified investors through an accelerated bookbuilding process. Demand exceeded the offer several times over.
The new shares represent roughly 20% of Amplifon's pre-increase share capital. Settlement is expected on May 26.
Key shareholders Ampliter Srl and Tamburi Investment PartnersDealroom has a profile for this one. Try Dealroom → committed €100M and €30M respectively. After the transaction, Ampliter will retain control with approximately 38.69% of share capital and 70.09% of voting rights.
Why now? The proceeds will go entirely towards financing the cash component of Amplifon's acquisition of GN Store Nord's hearing business — a deal that requires significant upfront capital. The accelerated bookbuilding approach suggests urgency to lock in funding while investor appetite is strong.
What could go wrong? The 20% dilution is substantial for existing shareholders who didn't participate. Integration of GN Store Nord's hearing division will be the real test — large acquisitions in healthcare carry execution risk, from regulatory hurdles to cultural clashes between organisations.
If market conditions shift or the acquisition hits snags, Amplifon could find itself with diluted equity and an incomplete deal.
The signal: Amplifon is already recognised as a global leader in the hearing care retail market, and absorbing GN Store Nord's hearing division would significantly extend that dominance. The strong backing from investment fund Tamburi Investment Partners and controlling shareholder Ampliter — combined with oversubscribed demand — suggests institutional confidence that consolidation in hearing care will reward scale as demographics drive long-term demand.
Read more: ae.marketscreener.com
